Welcome to our dedicated page for Nexgel SEC filings (Ticker: NXGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NEXGEL, Inc. (NASDAQ: NXGL) SEC filings page brings together the company’s official regulatory documents, giving investors direct insight into its hydrogel-focused healthcare and consumer products business. As a Delaware corporation listed on NASDAQ, NEXGEL files annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and proxy statements such as its definitive proxy on Schedule 14A.
In these filings, NEXGEL details its operations in ultra-gentle, high-water-content hydrogel products, its contract manufacturing relationships with consumer healthcare companies, and its portfolio of brands including SilverSeal®, Hexagels®, Turfguard®, Kenkoderm® and Silly George®. Financial statements and accompanying notes explain revenue from contract manufacturing and branded products, gross profit, operating expenses, and net loss attributable to NEXGEL stockholders.
Current reports on Form 8-K provide timely disclosure of material events, such as quarterly financial results, the spin-off of a portion of the drug delivery program into NexGelRx, changes in executive leadership, and decisions by the board of directors regarding special meetings or capital structure proposals. Proxy materials, including the company’s definitive proxy statement for a special meeting of stockholders, describe matters submitted to shareholder vote, such as proposed amendments to the certificate of incorporation.
Through this page, users can also review filings related to equity offerings, warrants, and other securities matters referenced in NEXGEL’s disclosures. Real-time updates from the SEC’s EDGAR system ensure that new NXGL filings appear promptly, while AI-powered summaries help explain the key points of lengthy documents, including complex sections on non-GAAP financial measures, risk factors, and governance provisions.
For those analyzing NXGL, this SEC filings archive offers a structured view of how NEXGEL reports its business, finances, and corporate actions over time, directly from its official submissions to regulators.
NEXGEL (NXGL) reported an insider transaction on a Form 4. The Chief Executive Officer and Director sold 4,000 shares of common stock on 11/06/2025 at a $2.5211 weighted average price, pursuant to a Rule 10b5-1 trading plan.
Following the sale, the reporting person beneficially owns 367,692 shares, held directly. The price reflects multiple open-market sales within the $2.500–$2.5500 range.
NexGel, Inc. plans a special stockholder vote on an Authorized Share Increase. The proposal asks investors to approve—if and only if the Board later approves and implements—an amendment to raise authorized common stock from 25,000,000 to 1,000,000,000 shares, with total authorized capital increasing to 1,005,000,000 shares. The Board unanimously recommends a “FOR” vote.
The company cites future flexibility for capital raising, acquisitions, partnerships, and other corporate needs. Existing rights of common stock would remain the same, and preferred stock authorization stays at 5,000,000. The filing notes potential dilution if additional shares are issued in the future and acknowledges possible anti‑takeover effects, while stating the proposal is not in response to any control effort. Stockholders of record as of October 20, 2025 may vote; 8,142,766 common shares were outstanding as of that date.
NexGel, Inc. is asking stockholders to approve a major increase in authorized common shares—from 25,000,000 to 1,000,000,000—“if and only if” the Board later approves and implements the change. The vote will be held at 10:00 a.m. ET on November 26, 2025, at the company’s Langhorne, PA headquarters.
The Board unanimously recommends a “FOR” vote. The proposal requires the affirmative vote of a majority of total outstanding shares entitled to vote. Brokers have discretionary authority to vote on this proposal, and no appraisal rights apply.
The company cites future flexibility to raise capital, pursue acquisitions, joint ventures, and other corporate needs. The amendment itself has no immediate effect on ownership or voting power, but future issuances could dilute existing holders. As of October 20, 2025, shares outstanding were 8,142,766. If approved, the Board may effect the increase within twelve months by filing a Certificate of Amendment with Delaware.
NEXGEL, Inc. (NXGL) director Robert Henry Scott reported open-market sales under a Rule 10b5-1 plan. The earliest transaction date is
NEXGEL (NXGL)
He sold 1,600 shares on 10/02/2025 at $2.5000 per share and 2,400 shares on 10/03/2025 at a weighted average price of $2.5497, with individual trades ranging from $2.5000 to $2.6100. After these transactions, he beneficially owned 371,692 shares.
Nexgel, Inc. (NXGL) filed a Form 144 reporting a proposed sale of 16,000 common shares with an aggregate market value of $40,000.00. The shares were originally acquired on 10/15/2019 as compensation from the issuer. The filing lists approximately 8,067,580 shares outstanding and names The Charles Schwab Corporation as the broker with an approximate sale date of 10/02/2025 on NASDAQ. The filer also reported a prior sale of 4,000 shares on 08/28/2025 for gross proceeds of $9,896.00. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
NEXGEL director Henry Scott Robert sold 7,697 shares of the company's common stock on 09/25/2025 under a pre-established Rule 10b5-1 trading plan at a weighted average price of $2.3579 per share. The shares were originally purchased on 03/01/2024. After the sale, the reporting person beneficially owns 121,356 shares, held directly. The filer notes the sale prices ranged from $2.3500 to $2.3900 and offers to provide a breakdown of shares sold at each price if requested.
Form 144 notice for proposed sale of common stock. The filing shows 35,515 shares of common stock are proposed for sale through The Charles Schwab Corporation, with an aggregate market value of $108,451 and 8,067,580 shares outstanding. The securities were acquired as compensation on 02/15/2024 in a transaction described as "COMPENSATION / DEAL ACQUIRED BETWEEN: 2/15/24 TO 11/5/24" and payment is recorded as of 02/15/2024. The filer reports no securities sold during the past three months. The notice includes the standard representation that the seller is not aware of any undisclosed material adverse information.